- Conditions
- Type II Diabetes
- Interventions
- Placebo, Sitagliptin, LEZ763
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 735
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertriglyceridemia
- Interventions
- POM3, Placebo
- Drug
- Lead sponsor
- Provident Clinical Research
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Addison, Illinois
- Conditions
- Metabolic Syndrome
- Interventions
- intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Gastrointestinal Dysmotility
- Interventions
- Ulimorelin Intravenously (IV), 5% dextrose in water
- Drug
- Lead sponsor
- Tranzyme, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 23
- States / cities
- Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more
- Conditions
- Dietary Supplementations
- Interventions
- Carbohydrate, Carbohydrate-Protein, Placebo
- Dietary Supplement
- Lead sponsor
- Erica Goldstein
- Other
- Eligibility
- 35 Years to 59 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- PreDiabetes, Blood Glucose, High
- Interventions
- Cinnamon, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
- Interventions
- PZ-128, Placebo
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Obesity, Dysglycemia
- Interventions
- Betaine, Placebo
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bone Metabolism
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 70 Years · Female only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Greenbrae, California • Los Banos, California • San Diego, California + 31 more
- Conditions
- Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
- Interventions
- Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
- Interventions
- Milrinone, Placebo (5% Dextrose)
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 0 Hours to 168 Hours
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg
- Drug · Other
- Lead sponsor
- Oramed, Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Tyrosol, Creatine, Endurance Performance, Cognition, Mood
- Interventions
- Tyrosol, Creatine Monohydrate, Resistant Dextrin
- Dietary Supplement
- Lead sponsor
- Applied Science & Performance Institute
- Industry
- Eligibility
- 20 Years to 55 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Urinary Urge Incontinence
- Interventions
- Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Pomegranate Juice, Placebo Juice
- Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Interventions
- Levosimendan, Matching Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
- Conditions
- Intestinal Health
- Interventions
- "Humanized" galacto-oligosaccharides (hGOS), Galacto-oligosaccharides (GOS), Matching Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Influenza
- Interventions
- CR8020, CR6261, Placebo
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 21
- States / cities
- Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Pulmonary Hypertension, Familial Persistent, of the Newborn
- Interventions
- placebo, iv sildenafil
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 0 Days to 4 Days
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
- Interventions
- Rosiglitazone, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Gastroparesis, Diabetes Mellitus
- Interventions
- 5% dextrose in water, TZP-101
- Drug
- Lead sponsor
- Tranzyme, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 6
- States / cities
- San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
- Conditions
- Healthy
- Interventions
- PNT001, Placebo
- Biological · Drug
- Lead sponsor
- Pinteon Therapeutics, Inc
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Rogers, Arkansas • San Diego, California • Marlton, New Jersey + 1 more
- Conditions
- Metabolic Syndrome X
- Interventions
- NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin